



CNIO Frontiers Meetings

Cancer Pharmacogenetics: personalizing medicine

Madrid, November 22-24, 2010

Organisers

Javier Benítez, CNIO, Madrid, Spain
William E. Evans, St. Jude Children's Research Hospital, Memphis, USA
Magnus Ingelman-Sundberg, Karolinska Institutet, Stockholm, Sweden
Miguel Martín, Hospital Gregorio Marañón, Madrid, Spain

MONDAY, NOVEMBER 22

9:15-9:30 **Welcome address**

Javier Benítez, CNIO, Madrid, Spain

Session I: Inherited and somatic genetic variation and cancer pharmacotherapy

Chair: tba

- 9:30-10:05 **Magnus Ingelman-Sundberg**, Karolinska Institutet, Stockholm, Sweden
Topic: The pharmacogenetics and epigenomics of drug response
- 10:05-10:40 **Alex Sparreboom**, St. Jude Children's Research Hospital, Memphis, USA
Topic: Drug transporters
- 10:40-11:15 **Julian Downward**, Cancer Research UK London Research Institute, London, UK
Topic: Pharmacodynamics
- 11:15-11:45 *Coffee break and poster session*
- 11:45-12:20 **Anna Di Rienzo**, The University of Chicago, Chicago, USA
Topic: Population genetics
- 12:20-12:55 **Peter Campbell**, Wellcome Trust Sanger Institute, Cambridge, UK
Topic: The International Cancer Genome Consortium
- 12:55-13:10 Short talk # 1
- 13:10-13:25 Short talk # 2
- 13:30-15:00 *Lunch and poster session*

Session II: Pharmacogenomic and epigenomic determinants of anti-cancer drug efficacy

Chair: tba

- 15:00-15:35 **David A. Flockhart**, Indiana University School of Medicine, Indianapolis, USA
Topic: Breast cancer: tamoxifen and aromatase inhibitors
- 15:35-16:10 **Rafael Rosell**, Institut Català d'Oncologia (ICO), Barcelona, Spain
Topic: Lung cancer- targeted drugs "Personalizing targeted therapies in lung cancer"
- 16:10-16:40 *Coffee break and poster session*
- 16:40-17:15 **Manel Esteller**, Institut Català d'Oncologia (ICO), Barcelona, Spain
Topic: Epigenomics and cancer treatment
- 17:15-17:30 Short talk #3
- 17:30-17:45 Short talk # 4

TUESDAY, NOVEMBER 23

Session III: Pharmacogenetics of cancer adverse effects

Chair: tba

- 9:30-10:05 **William E. Evans**, St. Jude Children's Research Hospital, Memphis, USA
Topic: ALL therapy
- 10:05-10:40 **Howard McLeod**, University of North Carolina, Chapel Hill, USA
Topic: Colorectal cancer
- 10:40-11:15 **Anna Gonzalez- Neira**, CNIO, Madrid, Spain
Topic: Breast cancer
- 11:15-11:45 *Group picture, coffee break and poster session*
- 11:45-12:20 **Cristina Rodríguez-Antona**, CNIO, Madrid, Spain
Topic: Microtubule-targeted drugs
- 12:20-12:35 Short talk #5
- 12:35-12:50 Short talk # 6
- 13:00-14:30 *Lunch and poster session*

Sesion IV: State-of-the-art in high-throughput technologies and bioinformatic tools for pharmacogenetics

Chair: tba

- 14:30-15:05 **Jörg D. Hoheisel**, German Cancer Research Center (DKFZ), Heidelberg, Germany
*Topic: Functional analysis “**Functional Genomics and Proteomics in Cancer Research**”*
- 15:05-15:40 **Javier Benítez**, CNIO, Madrid, Spain
Topic: HT Genotyping platforms/ Next-generation sequencing technology
- 15:40-16:15 **Arcadi Navarro**, *Universitat Pompeu Fabra*, Barcelona, Spain
Topic: Bioinformatic tools and in silico predictions
- 16:15-16:45 *Coffee break and poster session*
- 16:45-17:20 **Teri E. Klein**, Stanford University Medical Center, Stanford, USA
Topic: Pharmacogenetics databases
- 17:20-17:35 Short talk # 7
- 17:35-17:50 Short talk # 8

WEDNESDAY, NOVEMBER 24

Session V: Implementing Pharmacogenetics: how industry, regulators, clinicians and policymakers are shaping the field

Chair: tba

- 9:30-10:05 **Miguel Martin**, Hospital Gregorio Marañón, Madrid, Spain
Topic: Clinical trials
- 10:05-10:40 **Ron Van Schaik**, Erasmus University Medical Center, Rotterdam, The Netherlands
Topic: Barriers for pharmacogenetics implementation
- 10:40-11:15 **Robert Wasserman**, Hoffmann La Roche, Nutley, USA
Topic: Drug Discovery
- 11:15-11:45 *Coffee break and poster session*
- 11:45-12:20 **Eric Abadie**, Committee for Medicinal Products for Human Use, European Medicines Agency
Topic: Regulatory agencies

12:20 Closing remarks and poster prize

Magnus Ingelman-Sundberg, *Karolinska Institutet*, Stockholm, Sweden



Note: Talks: 25 minutes Discussion: 10 minutes after each talk

8 Short talks 10 minutes each Discussion: 5 minutes after each short talk

You can send us your abstract. 8 short talks will be selected from the submitted abstracts

Abstracts should only be submitted via on-line